tropifexor tropifexor tropifexor is an investigational drug that acts as an agonist of the farnesoid x receptor (fxr). it was discovered by researchers from novartis and genomics institute of the novartis research foundation. its synthesis and pharmacological properties were published in 2017. it was developed for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (nash). in combination with cenicriviroc, a ccr2 and ccr5 receptor inhibitor, it is undergoing a phase ii clinical trial for nash and liver fibrosis. tropifexorclinical dataatc codenoneidentifiers iupac name 2--1,2-oxazol-4-yl]methoxy]-8-azabicyclooctan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid cas number1383816-29-2pubchem cid121418176uniinmz08km76zkeggd11548chemical and physical dataformulac29h25f4n3o5smolar mass603.59 g·mol−13d model (jsmol)interactive image smiles c1c2cc(c1n2c3=nc4=c(c=c(c=c4s3)c(=o)o)f)occ5=c(on=c5c6=cc=cc=c6oc(f)(f)f)c7cc7 inchi inchi=1s/c29h25f4n3o5s/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18h,5-8,11-13h2,(h,37,38)/t16-,17+,18+key:vylooghlksnnek-piimjckosa-n rats treated orally with tropifexor (0.03 to 1 mg/kg) showed an upregulation of the fxr target genes, bsep and shp, and a down-regulation of cyp8b1. its ec50 for fxr is between 0.2 and 0.26 nm depending on the biochemical assay. the patent that covers tropifexor and related compounds was published in 2010.